EP2661260A4 - Formulations de benzimidazole à libération modifiée - Google Patents

Formulations de benzimidazole à libération modifiée

Info

Publication number
EP2661260A4
EP2661260A4 EP11853533.5A EP11853533A EP2661260A4 EP 2661260 A4 EP2661260 A4 EP 2661260A4 EP 11853533 A EP11853533 A EP 11853533A EP 2661260 A4 EP2661260 A4 EP 2661260A4
Authority
EP
European Patent Office
Prior art keywords
modified release
benzimidazole
formulations
benzimidazole formulations
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11853533.5A
Other languages
German (de)
English (en)
Other versions
EP2661260A2 (fr
Inventor
Lingam Meka
Srinivasa Almareddy Reddy
Vagisha Sinha
Hitesh Jogia
Srinivas Arutla
Raviraj Pillai
Rahul Sudhakar Gawande
Prasad Vure
Venkateswarlu Vobalaboina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd, Dr Reddys Laboratories Inc filed Critical Dr Reddys Laboratories Ltd
Publication of EP2661260A2 publication Critical patent/EP2661260A2/fr
Publication of EP2661260A4 publication Critical patent/EP2661260A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11853533.5A 2010-12-29 2011-12-29 Formulations de benzimidazole à libération modifiée Withdrawn EP2661260A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4013CH2010 2010-12-29
US201161447759P 2011-03-01 2011-03-01
PCT/US2011/067868 WO2012092486A2 (fr) 2010-12-29 2011-12-29 Formulations de benzimidazole à libération modifiée

Publications (2)

Publication Number Publication Date
EP2661260A2 EP2661260A2 (fr) 2013-11-13
EP2661260A4 true EP2661260A4 (fr) 2014-05-14

Family

ID=46383862

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11853533.5A Withdrawn EP2661260A4 (fr) 2010-12-29 2011-12-29 Formulations de benzimidazole à libération modifiée

Country Status (7)

Country Link
EP (1) EP2661260A4 (fr)
CN (1) CN103402501A (fr)
AU (1) AU2011352037A1 (fr)
EA (1) EA201390979A1 (fr)
NZ (1) NZ613090A (fr)
UA (1) UA112855C2 (fr)
WO (1) WO2012092486A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2773348B1 (fr) * 2011-11-02 2018-02-21 Laboratorios Del. Dr. Esteve, S.A. Compositions pharmaceutiques d'oméprazole
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (fr) * 2013-03-15 2014-09-18 Aihol Corporation Formulation pharmaceutique contenant un glycosaminoglycane
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN112336696B (zh) * 2020-12-01 2022-08-05 苏州中化药品工业有限公司 一种长效脉冲制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013868A1 (en) * 2002-10-16 2006-01-19 Yohko Akiyama Controlled release preparation
US20080095853A1 (en) * 2004-11-04 2008-04-24 Niclas Clemmensen Modified Release For Proton Pump Inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
JP4541807B2 (ja) * 2004-09-03 2010-09-08 Ｏｋｉセミコンダクタ株式会社 半導体素子保持装置および半導体素子の搬送方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
US20090214599A1 (en) * 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013868A1 (en) * 2002-10-16 2006-01-19 Yohko Akiyama Controlled release preparation
US20080095853A1 (en) * 2004-11-04 2008-04-24 Niclas Clemmensen Modified Release For Proton Pump Inhibitors

Also Published As

Publication number Publication date
EA201390979A1 (ru) 2013-12-30
UA112855C2 (uk) 2016-11-10
WO2012092486A2 (fr) 2012-07-05
EP2661260A2 (fr) 2013-11-13
CN103402501A (zh) 2013-11-20
NZ613090A (en) 2015-11-27
WO2012092486A3 (fr) 2012-11-01
AU2011352037A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
HRP20161771T1 (hr) Formulacije bendamustina
EP2637696A4 (fr) Composition à libération prolongée
IL217153A0 (en) Controlled release formulations
EP2537907A4 (fr) Composition d'agent antiadhésif
HK1208222A1 (en) Modified release formulations for oprozomib
EP2661260A4 (fr) Formulations de benzimidazole à libération modifiée
EP2595660A4 (fr) Compositions bendamustine- cyclopolysaccharides anioniques-cationiques
ZA201300194B (en) Formulations
HK1172255A1 (en) Extended release preparation
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201001335D0 (en) Drug release formulations
GB201018647D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130626

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140416

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101ALI20140410BHEP

Ipc: A61K 9/48 20060101ALI20140410BHEP

Ipc: A61K 31/4439 20060101AFI20140410BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170411